Recent developments in mobile health bring forth an important debate regarding the role of the Food and Drug Administration (FDA) in regulating and monitoring mobile health applications.
Some argue that the FDA’s role could encourage further investments because investors would be able to predict how the regulator will respond to a new product.. Others claim that the FDA need not keep track of every change that happens in this fast growing environment. In fact, entities other than the FDA could play a role in monitoring and evaluation of these apps. Intertwined in this debate is the important question of privacy - new technologies might not have traditional authentication methods. Take Google Glass, for example: it does not require users to enter a username or password.
While we want to foster innovation, we cannot neglect the safety and privacy of patients. In light of this argument, I am curious to hear from members about their perspectives on what should be the priority - innovation or regulation? Can they go hand in hand? Where should the FDA come in?
Link leads to: http://www.clinical-innovation.com/topics/mobile-telehealth/oversight-privacy-s-impact-mhealth